When does the presence of the target predict response to the targeted agent?
Bergsland
Emily K
EK
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D006801:Humans; D012333:RNA, Messenger / Q000032:analysis; D019699:Thrombospondins / Q000032:analysis* / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics; D000099262:Thrombospondin 2
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D012333:RNA, Messenger; D019699:Thrombospondins; D042461:Vascular Endothelial Growth Factor A; D000099262:Thrombospondin 2; C467484:VEGFA protein, human